It has been reported that the hyperinsulinism-hyperammonemia syndrome is caused by mutations in glutamate dehydrogenase (GDH) gene that affects enzyme sensitivity to GTP-induced inhibition. To identify the GTP binding site(s) within human GDH, mutant GDHs at Tyr-266 or Lys-450 position were constructed by cassette mutagenesis. More than 90% of the initial activities were remained at the concentration of GTP up to 300 M for the Lys-450 mutant GDHs regardless of their size, hydrophobicity, and ionization of the side chains, whereas the wild type GDH and the Tyr-266 mutant 32 P]GTP was significantly decreased in the presence of 300 M GTP. Unlike the wild type GDH or the Tyr-266 mutant GDH, less than 10% of photoinsertion was detected in the Lys-450 mutant GDH, and the photoinsertion was not affected by the presence of 300 M GTP. The results with cassette mutagenesis and photoaffinity labeling demonstrate selectivity of the photoprobe for the GTP binding site and suggest that Lys-450, but not Tyr-266, is required for efficient binding of GTP to GDH. Interestingly, studies of the steady-state velocity showed that both the wild type GDH and the Tyr-266 mutant GDHs were inhibited by ATP at concentrations between 10 and 100 M, whereas less than 10% of the initial activities of the Lys-450 mutant GDHs were diminished by ATP. These results indicate that Lys-450, but not Tyr-266, may be also responsible for the ATP inhibition; therefore, ATP bound to the GTP site.
Glutamate dehydrogenase (GDH) 1 has been isolated and sequenced from a number of varied sources and has an important role in nitrogen and carbon catabolism. GDH (EC 1.4.1.2-1.4.1.4) catalyzes the reversible deamination of L-glutamate to 2-oxoglutarate using NAD ϩ or NADP ϩ as coenzyme (1) . The largest difference between mammalian and bacterial GDH is a long antenna domain formed by the 48-amino acid insertion extending from the top of the NAD domain and lying adjacent to the 3-fold axis of the hexamer (2) (3) (4) (5) , and there is little identity between the 100 residues in the C terminus (6) . In contrast to the extensive allosteric homotrophic and heterotrophic regulation observed in mammalian GDH, bacterial forms of GDH are relatively unregulated. The recent atomic structure of bovine liver GDH suggests that the allosteric regulation and negative cooperativity observed in mammalian GDH may be facilitated by the subunit interactions within the antenna region (4, 5) . It was suggested that these allosteric regulations are performed by changing the energy required to open and close the catalytic cleft during enzymatic turnover (4) .
Mammalian GDH is strictly regulated by several allosteric effectors. GTP inhibits enzyme turnover over a wide range of conditions by increasing the affinity of the enzyme for the product, making product release rate-limiting under all conditions in the presence of GTP (4, 5, 7) . In contrast, ADP is a potent activator by decreasing product affinity (8, 9) . Binding studies suggest that when NADH is used as a coenzyme, there are two GTP sites per subunit (10) , and GTP inhibition is agonized by synergistic binding between the second coenzyme and one of the GTP binding sites (11) . It also has been reported that mammalian GDH contains both an NADH-dependent and NADH-independent GTP binding site (7) . However, there are disagreements on whether there are two GTP sites (4, 5, 7, 12, 13) . Recently, Peterson and Smith (4) report, based on their atomic structure studies, that a second GTP molecule binds into the region below the pivot helix that lies behind the NAD ϩ binding domain. Paradoxically, NAD ϩ can also bind to the second GTP site but causes activation. Very recently, the strongest evidence that this was not a bound GTP molecule came from the same researchers (5) . It appears that the region below the pivot helix is the second coenzyme site rather than a second GTP site (5) .
The importance of the physiological nature of GDH has attracted considerable interest. The existence of the hyperinsulinism-hyperammonemia syndrome caused by mutations in a human GDH gene that affects enzyme sensitivity to GTPinduced inhibition highlights further the importance of GDH (14 -16) . The hyperinsulinism-hyperammonemia syndrome could be caused by excessive activity of GDH, since this would simultaneously increase the release of insulin by pancreatic beta cells. These observations demonstrate that allosteric regulation of GDH plays a crucial role in the regulation of insulin secretion and hepatic ureagenesis. The mutated residues responsible for this pathology were found to lie mainly around the GTP site (16) .
In the present work, we have expanded on the identification of GTP binding site(s) of human GDH using a cassette mutagenesis and photoaffinity labeling with 8-N 3 -GTP at two residues, Tyr-266 and Lys-450, that have been speculated as putative GTP binding sites by chemical modification studies (7, 12, 13) and found to be involved in hyperinsulinism-hyperammonemia syndrome (16) . Azidopurine photoprobes generate short-lived, very reactive nitrenes that will modify any residue placed near the generated nitrene by binding. The ability of the photoaffinity probes in the absence of activating light to mimic the native nucleotides as substrate and regulatory constituents further supports their specificity. Their selectivity and specificity have been successfully utilized to locate specific binding domains on mammalian GDH and other proteins (17) (18) (19) (20) (21) (22) .
Very recently, a 1557-base pair gene that encodes human GDH has been synthesized and expressed in Escherichia coli in our laboratory (23) . For the present study, the mutant human GDHs, containing Glu, Gly, Met, Ser, or Arg at the Tyr-266 site and Glu, Gly, Met, Ser, or Tyr at the Lys-450 site have been expressed in E. coli as a soluble protein, purified, and characterized. To our knowledge, this is the first report by sitedirected mutagenesis showing that Lys-450, but not Tyr-266, is required for efficient binding of GTP and that the second GTP site, if any, is not required for binding of GTP to human GDH.
EXPERIMENTAL PROCEDURES

Materials-NADP
ϩ , NAD ϩ , NADH, NADPH, 2-oxoglutarate, ATP, ADP, isopropyl ␤-D-thiogalactopyranoside, GTP, L-glutamate, and L-1-tosylamido-2-phenylethyl chloromethyl ketone-treated trypsin were purchased from Sigma. 8-N 3 -[␥-
32 P]GTP was synthesized by the method as previously described (12, 13) . Human GDH gene (pHGDH) has been chemically synthesized and expressed in E. coli as a soluble protein in our laboratory as described elsewhere (23) . All other chemicals and solvents were reagent grade or better.
Bacterial Strains-E. coli DH5␣ (24) was used as the host strain for plasmid-mediated transformations for cassette mutagenesis. E. coli PA340 (thr-1 fhuA2 leuB6 lacY1 supE44 gal-6 gdh-1 hisG1 rfbD1 galP63 ⌬(gltB-F)500 rpsL19 malT1 xyl-7 mtl-2 argH1 thi-1 (kindly provided by Dr. Mary K. B. Berlyn, E. coli Genetic Stock Center, Yale University) lacked both GDH and glutamate synthase activities (25) and was used to test plasmids for GDH activity. E. coli BL21 (DE3) (26) was used for high level expression of the recombinant human GDH.
Construction and Characterization of Tyr-266 Mutants and Lys-450
Mutants-A series of single amino acid substitutions of Tyr-266 or Lys-450 was constructed separately by cassette mutagenesis of a synthetic human GDH gene, pHGDH (23) . For, the Tyr-266 site, plasmid DNA (5 g) was digested with StuI and NsiI to remove a 42-bp fragment that encodes amino acids 260 -273; this fragment was replaced with five 42-bp synthetic DNA duplexes containing a substitution on both DNA strands at positions encoding Tyr-266 to make Y266G, Y266S, Y266E, Y266M, and Y266R. For mutagenesis at the Lys-450 site, plasmid DNA was digested with NheI and Tth111I to remove a 15-bp fragment that encodes amino acids 447-451; this fragment was replaced with five 15-bp synthetic DNA duplexes containing a substitution on both DNA strand at positions encoding Lys-450 to make K450G, K450S, K450E, K450M, and K450Y. The Tyr-266 mutant GDHs and the Lys-450 mutant GDHs were identified by DNA sequencing using plasmid DNA as a template. Each of these mutants has been expressed in E. coli strain DE3, has been purified to homogeneity as described above, and has had its steady-state kinetic parameters determined. The gene expression levels of the Tyr-266 mutant GDHs and the Lys-450 mutant GDHs were examined by Western blot and compared with those of wild type GDH.
Purification and Characterization of Mutant GDHs-Fresh overnight cultures of DE3/pHGDH were used to inoculate 1 liter of LB containing 100 g of ampicillin/ml. DE3/pHGDH was grown at 37°C until the A 600 reached 1.0, and then isopropyl ␤-D-thiogalactopyranoside was added to a final concentration of 1 mM. After isopropyl ␤-Dthiogalactopyranoside induction, DE3/pHGDH was grown for an additional 3 h at 37°C and then harvested by centrifugation. Cell pellets were suspended in 100 ml of 100 mM Tris-HCl, pH 7.4, 1 mM EDTA, 5 mM dithiothreitol and lysed with a sonicator. The wild type GDH and the mutant GDHs were purified by the method developed in our laboratory (23, 27) . Because the wild type GDH and the mutant GDHs were readily solubilized, no detergents were required throughout the entire purification steps. The purified GDHs were analyzed by SDS/PAGE and recognized by Western blot using monoclonal antibodies previously produced in our laboratory (28) against the bovine brain GDH. Protein concentration was determined as described previously (27) .
Enzyme Assay and Kinetic Studies-GDH activity was measured spectrophotometrically in the direction of reductive amination of 2-oxoglutarate by following the decrease in absorbance at 340 nm as described before (27) . All assays were performed in duplicate, and initial velocity data were correlated with a standard assay mixture containing 50 mM triethanolamine, pH 8.0, 100 mM ammonium acetate, 0.1 mM NADH, 10 mM 2-oxoglutarate, and 2.6 mM EDTA at 25°C. Because E. coli only has an NADP(H)-dependent GDH (24, 29) , the enzyme assay was performed with NADH as a coenzyme as described elsewhere (27) . One unit of enzyme was defined as the amount of enzyme required to oxidize 1 mol of NADH/min at 25°C. The effects of the wild type GDH and the mutant GDHs by allosteric regulators such as GTP, ADP, and ATP were examined by incubating the enzymes with the allosteric effectors at various concentrations in 50 mM triethanolamine, pH 8.0, at 25°C. At intervals after the initiation with the effectors, aliquots were withdrawn for the assay of GDH activity.
Photolabeling of GDH-Photolabeling of the wild type GDH and the mutant GDHs were performed by the method of Shoemaker and Haley (12) P]GTP and then allowed to incubate with the photoprobe for 5 min as described above. The samples were then irradiated with a handhold 254-nm UV lamp for 90 s twice at 4°C. The reaction was quenched by the addition of ice-cold trichloroacetic acid (final 7%). The reaction mixtures were kept on ice bath for 30 min and then centrifuged at 10,000 ϫ g for 15 min at 4°C. The pellets were washed and resuspended with 10 mM Tris acetate, pH 8.0. The remaining free photoprobe, if any, was further removed from the protein by exhaustive washing using Centrifree (Amicon), and 32 P incorporation into protein was determined by liquid scintillation counting.
Tryptic Digestion and Isolation of Photolabeled Peptide-1.0 mg of the wild type GDH and the mutant GDHs in 5 mM Tris acetate, pH 8.0, were separately incubated with 100 M 8-N 3 -[␥-
32 P]GTP for 2 min at 4°C. The mixtures were irradiated for 90 s twice. The reaction was quenched by the addition of ice-cold trichloroacetic acid (final 7%) and kept at 4°C for 15 min. The protein was precipitated by centrifugation at 10,000 ϫ g for 15 min at 4°C, and the pellet was resuspended in 75 mM NH 4 HCO 3 , pH 8.5, containing 2 M urea. The resuspended sample was proteolysed by the addition of 15 g of trypsin and kept at room temperature for 3 h, after which 15 g of trypsin was added again. After 3 more h at room temperature, 15 g of trypsin was added, and the digestion mixture was kept at 25°C overnight. To validate that the isolated peptide(s) was specific for the GTP site and so could be protected by GTP from photomodification, GDH was photolysed in the presence of 300 M GTP and proteolysed as described above. The photolabeled GDHs in the presence or absence of 300 M GTP were applied to a Protein Pak DEAE-5PW (Waters) column on a Waters HPLC system equipped with a diode array spectral detector. The gradient for HPLC was 0 -10 min, 0% NaCl; 10 -60 min, 0 -0.5 N NaCl; 60 -70 min, 0.5 N NaCl at a flow rate of 0.5 ml/min. The absorbance of the fractions was measured at 220 nm, and the photoincorporation was determined by liquid scintillation counting. The fractions containing photolabeled peptides were desalted, freeze-dried, resuspended in 0.1% trifluoroacetic acid, and subjected to reversed-phase HPLC using a Waters C 18 column on the same HPLC system. The mobile system consisted of 0.1% trifluoroacetic acid solution and 0.1% trifluoroacetic acid, 80% acetonitrile solvent system. The gradient for HPLC was 0 -10 min, 0% acetonitrile; 10 -60 min, 0 -80% acetonitrile; 60 -70 min, 80% acetonitrile at a flow rate of 0.5 ml/min. HPLC fractions containing photolabeled peptides were sequenced by the Edman degradation method as described elsewhere (27) .
RESULTS
Construction and Expression of Tyr-266 Mutants and Lys-450 Mutants-The 42-bp StuI/NsiI fragment and the 15-bp
NheI/Tth111I fragment in pHGDH were replaced with five 42-and 15-bp synthetic DNA duplexes containing a substitution on both DNA strands at positions encoding Tyr-266 and Lys-450, respectively. These substitutions created the mutant GDHs Y266G, Y266S, Y266E, Y266M, and Y266R at position 266 and K450G, K450S, K450E, K450M, and K450Y at position 450, respectively. These mutants were designed to have different size, hydrophobicity, and ionization of the side chains at each position. Analysis of crude cell extracts by Western blot showed that Tyr-266 or Lys-450 mutant plasmids encoding an amino acid substitution at position 266 or 450 directed the synthesis of a 56.5-kDa protein that interacted with monoclonal antibodies raised against GDH at almost identical levels for all mutant GDHs and wild type GDH (Fig. 1) . These results indicate that the mutagenesis at Tyr-266 or Lys-450 site has no effects on expression or stability of the different mutant GDHs.
Specific activities of the Tyr-266 mutant GDHs in the crude extracts were 0.25ϳ0.31 units/mg, compared with wild type value of 1.12 units/mg. This represent an ϳ4-fold reduction in the activities of the Tyr-266 mutant GDHs compared with wild type GDH, suggesting that Tyr-266 is required for catalytic activity. A more detailed investigation of the catalytic activities of the mutant enzymes revealed essentially unchanged apparent K m values for 2-oxoglutarate but a 3.5-fold decrease for NADH (Table I) with an ϳ4-fold decrease in the respective apparent V max values ( Table I ), suggesting that Tyr-266 may be located in the coenzyme binding domain. Unlike the Tyr-266 mutant GDHs, the Lys-450 mutant GDHs showed similar kinetic properties to those of the wild type GDH in terms of their specific activities, K m , and V max (Table I) .
Inactivation of Wild Type GDH and Mutant GDHs by GTP and 8-N 3 -GTP-
The inhibitory effects of GTP on the Tyr-266 mutant GDHs and the Lys-450 mutant GDHs were examined and summarized in Fig. 2 . There were significant differences between the Tyr-266 mutant GDHs and the Lys-450 mutant GDHs in their sensitivities to the inhibition by GTP (Fig. 2) . Although the wild type GDH and the Tyr-266 mutant GDHs were completely inhibited by GTP at 30 M, more than 90% of the initial activities remained at a GTP concentration up to 300 M for the Lys-450 mutant GDHs regardless of their size, hydrophobicity, and ionization of the side chains (Fig. 2) . These results suggest that the inhibition of GDH by GTP is mainly due to the binding of GTP to the Lys-450 residue and indicate that the Tyr-266 residue is not critically involved in the binding of GTP. The binding of GTP to the wild type GDH and the mutant GDHs was further examined by photoaffinity labeling with 8-N 3 -[␥-
32 P]GTP. To show that 8-N 3 -GTP could mimic the inhibitory properties of GTP, the photoanalogue should be able to reversibly inhibit GDH in the absence of activating light. When assayed with NADH as a coenzyme, 8-N 3 -GTP was able to inhibit the wild type GDH and the Tyr-266 mutant GDHs (Fig. 3) . However, less than 10% of the inhibitions by 8-N 3 -GTP in the reaction of the Lys-450 mutant GDHs were observed. These results show that the azidonucleotide 8-N 3 -GTP is able to elicit almost the same biological effects on the wild type GDH and the mutant GDHs as the natural nucleotide, GTP. Because almost identical results were obtained among the five mutant GDHs at position of Tyr-266 or Lys-450, respectively, only one mutant GDH at each position (Y266M and K450Y) was homogeneously purified for the further studies. The purified Y266M or K450Y mutant GDH was estimated to be Ͼ97% pure by SDS/PAGE (Fig. 4) .
Saturation and Competition of Photoinsertion-To show specificity of the photoprobe-protein interaction, saturation of photoinsertion should be observed. Under the experimental conditions described, saturation of photoinsertion with 8-N 3 -[␥-32 P]GTP occurred at 55 and 70 M photoprobe for the wild type GDH and the Y266M mutant GDH, respectively (Fig. 5) . The apparent K d values of this interaction were 18 and 22 M for the wild type GDH and the Y266M mutant GDH, respectively. However, the photoinsertion of 8-N 3 -[␥-
32 P]GTP into the K450Y mutant GDH was only 15% of the wild type GDH (Fig.  5) . To demonstrate specific labeling of GDH, the enzymes were photolabeled with 8-N 3 -[␥-
32 P]GTP in the presence of increasing GTP concentrations. As shown in the results of the competition experiments (Fig. 6) , increasing GTP concentration decreased the photolabeling of 60 M 8-N 3 -[␥-
32 P]GTP. When 300 M GTP was present with 100 M 8-N 3 -[␥-
32 P]GTP, 94 and 87% of photoinsertion were protected for the wild type GDH and the Y266M mutant GDH, respectively. For K450Y mutant GDH, there was a little effect of GTP on the photoinsertion of 8-N 3 -[␥-32 P]GTP, but this was a decrease from an already very low starting level (Fig. 6) . These results show the specificity and utility of 8-N 3 -GTP as a good candidate for determining the GTP site and suggest the involvement of Lys-450, but not Tyr-266, for the efficient binding of GTP to the human GDH.
Tryptic Digestion of Photolabeled Proteins and Isolation of the Photolabeled Peptide-To identify the peptides modified by 8-N 3 -[␥-
32 P]GTP, the enzymes were photolabeled twice in the absence or presence of 300 M GTP and digested with trypsin. A higher protein to nucleotide ratio was used to reduce any possible nonspecific labeling. The photolabeled GDH was separated from most of the noncovalently bound nucleotide by acid precipitation and proteolysed by trypsin. After overnight trypsin digestion of GDH modified with 8-N 3 -[␥-
32 P]GTP, the digested samples were purified by an anion-exchange column (Protein Pak DEAE-5PW, Waters). The results in Fig. 7A show the radioactivity profile of wild type GDH, Y266M mutant GDH, and K450Y mutant GDH modified by 60 M 8-N 3 -[␥-32 P]GTP in the absence of GTP. For the wild type GDH and the Y266M mutant GDH, most of the radioactivity was retained on the column, and one major radioactive peak around 0.25 N NaCl was recovered from the column. GTP was able to reduce 8-N 3 -[␥-
32 P]GTP photoinsertion into this peak. These results suggest that mutation at 266 position did not reduce the binding of GTP or 8-N 3 -[␥-
32 P]GTP to GDH. When 300 M GTP was originally present in the incubation mixture, more than 90% of the radioactivity of the peak was eliminated, as shown in Fig.  7B . Unlike the wild type GDH and the Y266M mutant GDH, there was only a very minor radioactive peak for the K450Y mutant GDH in the absence (Fig. 7A) or presence (Fig. 7B) of 300 M GTP. These results indicate that the radioactive peak represents a guanine binding domain peptide of the GTP binding site of human GDH, and so Lys-450, but not Tyr-266, is FIG. 3 . Inhibition of the wild type GDH and the mutant GDHs by 8-N 3 -GTP. The effects of 8-N 3 -GTP on the wild type GDH and the mutant GDHs were examined as described in Fig. 2 except that 8-N 32 P]GTP to GDH. For the wild type GDH and the Y266M mutant GDH, the radioactive eluates from the DEAE column were combined and subjected to reversed-phase HPLC. One major radioactive peak was clearly recovered from the HPLC column (data not shown). Although some radioactivity was found in the flow-through and wash fractions, more than 95% of the total radioactivity coeluted with the radioactive peak. The radioactivity associated with the HPLC flow-through fractions represents unbound probe including any decomposition products of photoadduct produced as peptide binds to the HPLC column matrix. These flow-through fractions were subjected to analysis, and no significant amounts of amino acids were detected. The radioactive eluates were collected and identified by sequence analysis. Because the radioactivity was very low for the K450Y mutant GDH, the absorption peak at 220 nm was monitored, and the peptide peak eluting with the same elution volume as those from the wild type GDH and the Y266M mutant GDH was used for the amino acid sequencing.
Sequence Analysis of the Photolabeled Peptide of the Wild Type GDH and Mutant GDHs-The results of the amino acid sequencing are summarized in Table II . The sequences obtained were also compared with those of various GDHs. The amino acid sequence analysis revealed that the peak fractions contained the amino acid sequence ISGASEXDIVHSGLAYT-MER for both the wild type GDH and the Y266M mutant GDH. This amino acid sequence of the photolabeled peptide is compatible with that of the tryptic peptide spanning residues Ile 444 -Arg 463 of the amino acid sequence of the mature human GDH. The symbol X indicates a position for which no phenylthiohydantoin-amino acid could be assigned. The missing residue X can be designated as a photolabeled lysine since the sequences including the lysine residue in question have a complete identity with those of the other GDH species known. In addition, trypsin was unable to cleave the photolabeled peptide at this site. Photolabeling of these peptides was prevented by the presence of 300 M GTP during photolysis. Unlike the wild type GDH and the Y266M mutant GDH, the K450Y mutant GDH showed a sequence of ISGASEYDIVHSGLAYTMER, and the photolabeling of this peptide was not affected by the presence of 300 M GTP during photolysis. No peptides containing amino acids around position 266 were detected with the wild type GDH and any mutant GDHs. Once again, these results strongly suggest that Lys-450, but not Tyr-266, is mainly involved in the binding of 8-N 3 -[␥-
32 P]GTP to GDH. ATP and ADP Effects on Human GDH Activity-Very recently atomic structure of bovine GDH has suggested that ATP, another well known allosteric inhibitor, may bind to the same site as GTP (5, 16). Studies of the steady-state velocity showed that both the wild type GDH and the Tyr-266 mutant GDHs were inhibited by ATP at concentrations between 0.01 and 0.1 mM, whereas none of the Lys-450 mutant GDHs was inhibited by ATP (Fig. 8A) . Unlike the effects of ATP, ADP at concentrations between 0.01 and 1.0 mM activated the reaction of the wild type GDH and mutant GDHs at Tyr-266 or Lys-450 position up to 2.5-fold (Fig. 8B ). There were no significant differences in their sensitivities to ADP activation between the wild type GDH and the mutant GDHs at Tyr-266 or Lys-450. These results further support a possibility that Lys-450, but not Tyr-266, is also responsible for the ATP inhibition, and ATP may inhibit the GDH reaction by binding to the GTP site.
DISCUSSION
It has been reported that the hyperinsulinism-hyperammonemia syndrome is caused by mutations in GDH gene that affect enzyme sensitivity to GTP-induced inhibition (16) . The atomic structure of bovine liver GDH (4, 5) has further supported that these mutations either have indirect effects on the GTP binding or on the allosteric effects caused by GTP. In either case, these results demonstrate the importance of GTP and the regulation of GDH activity in mammalian system. However, no direct experimental evidences have been reported to identify the specific amino acid residues involved in GTP binding. In the present work, we identified an amino acid required for the efficient binding of GTP to the human GDH using cassette mutagenesis, the photoaffinity labeling with 8-N 3 -[␥-
32 P]GTP, and inhibition studies. There were differences in their biochemical properties between the Tyr-266 mutant GDHs and the Lys-450 mutant GDHs. The Lys-450 mutant GDHs showed similar kinetic properties to those of the wild type GDH in terms of their specific activities and K m and V max values, whereas there were 4-fold reductions in V max values of the Tyr-266 mutant GDHs (Table  I) . The results from the Western blot analysis (Fig. 1) show that the mutagenesis at Tyr-266 or Lys-450 site has no effects on expression or stability of the different mutant GDHs. The reduction of the activities in the Tyr-266 mutant GDHs was as expected. Actually, the 266 position is quite closed to the coenzyme binding domain, as suggested by the most recent structure of bovine liver GDH (5). The increased K m values of the Tyr-266 mutant GDHs for NADH further support the possibil- ity that Tyr-266 may be involved in the coenzyme binding to the human GDH. Another difference between the Tyr-266 mutant GDHs and the Lys-450 mutant GDHs are their sensitivities to inhibition by GTP. The mutagenesis at position 450 resulted in a dramatic decrease in the sensitivities to the inhibition by GTP, and more than 90% of the initial activities remained at the GTP concentration up to 300 M regardless of their size, hydrophobicity, and ionization of the side chains (Fig. 2) . No such effects, however, were observed with the Tyr-266 mutant GDHs, and their initial activities were completely abolished by GTP at 0.02 mM. These results strongly suggest that the inhibition of GDH by GTP is mainly due to the binding of GTP to the Lys-450 residue.
It has been reported that mammalian GDH contains both an NADH-dependent and NADH-independent GTP binding site (7) . There are disagreements on whether there are two GTP binding sites (4, 5, 7, 12, 13) . Molecular genetic investigations in patients with the hyperinsulinism-hyperammonemia have revealed activating mutations of the GDH gene (16) . It has been reported that these mutations cluster within a range of 10 codons in exons 11 and 12 of the GDH gene (16) . This region has been suggested to encode the putative GTP allosteric domain of the enzyme (5, 30) and lie exactly within a sequence of 20 amino acids (Ile 444 -Arg 463 ) identified in the present study (Table II) . These mutations were associated with a diminished inhibitory effect of GTP on GDH activity of transformed lymphoblasts of affected patients and of COS-7 cells expressing the mutant enzyme. Recently, Yorifuji et al. (31) demonstrated mutations outside this domain. These mutations showed different enzyme kinetics characterized by an increased basal GDH activity (31) . More recently, novel heterozygous missense mutations in exon 6 (R221C) and 7 (R267H) were reported (32, 33) . Both mutations were shown to result in a normal basal activity but a diminished sensitivity to GTP. This is the first time that this effect is reported for mutations located in the presumed catalytic site and outside the GTP allosteric domain of the enzyme. The mechanism by which both the R221C and the R269H mutation result in diminished GTP sensitivity is not clear. Amino acid exchanges at these positions may cause a severe conformational change of the enzyme indirectly affecting the GTP binding. It is, however, also possible that these positions could be directly involved in GTP binding. When performing cross-linking studies, Colman (34) could identify the Arg-221 residue as a potential GTP binding site in bovine GDH.
In the present study, we have detected only one GTP binding site that is NADH-independent based on the following observations. NADH and NADPH reduced photolabeling of GDH with 8-N 3 -[␥- Finally, more than 90% of protection against to the inhibition by GTP up to 300 M were observed with all of the Lys-450 mutant GDHs, whereas the wild type GDH or the Tyr-266 mutant GDHs showed a complete lose of enzyme activity by GTP at the concentrations of 30 M GTP (Fig. 2) . These results indicate that there is only one GTP binding site and that the second GTP site, if any, is not required for efficient binding of GTP to human GDH. Our results obtained with human GDH are consistent with those obtained with bovine liver GDH (5, 12) and bovine brain GDH isoproteins (13) .
The specificity of 8-N 3 -GTP and the utility of this probe as a good candidate for determining the GTP site were demonstrated by the following. First, in the absence of activating light, GDH is inhibited by 8-N 3 -GTP as well as by GTP and can be photolabeled with the nucleotide analog 8-N 3 -[␥-
32 P]GTP. The ability to mimic a native compound before photolysis has an advantage over determination of the enzyme function after modification. Second, the photoinsertion into GDH was saturated with 55-70 M 8-N 3 -[␥-
32 P]GTP. The apparent K d values of this interaction were 18ϳ22 M (Fig. 5) . Third, the prevention of photoinsertion of 8-N 3 -[␥-32 P]GTP by GTP demonstrates that the photoprobe is inserting into a specific GTP site within GDH (Fig. 6) .
ADP and ATP have been shown to have opposite effects on GDH activity. ADP increases the reductive amination reaction velocity, whereas ATP inhibits the reaction at pH 8.0 and high NADH concentrations (8, 35) . Because the atomic structure of bovine GDH suggests that the ␥-phosphate of GTP dominates the GTP/GDH interactions (5), it is possible that ATP can bind to the GTP site. Kinetic analysis of a hyperinsulinism-hyperammonemia mutant also strongly suggests that ATP can inhibit GDH activity by binding to the GTP site (5, 16) . To test this possibility, effects of ATP and ADP on the activities of the wild type GDH, the Tyr-266 mutant GDHs, and the Lys-450 mutant GDHs of human GDH were observed. If ATP inhibition is due to binding to the GTP site, the mutant GDHs at the position of GTP binding site should not be inhibited by ATP but still activated by ADP. Studies of the steady-state velocity showed that both the wild type GDH and the Tyr-266 mutant GDHs were inhibited by ATP, whereas none of the Lys-450 mutant GDHs was inhibited by ATP (Fig. 8A) . Unlike the effects of ATP, there were no significant differences in their sensitivities to ADP activation between the Tyr-266 mutant GDHs and the Lys-450 mutant GDHs (Fig. 8B) . These results support a possibility that ATP can inhibit the GDH reaction by binding to the GTP site, and Lys-450, but not Tyr-266, is responsible for the ATP inhibition.
The construction of a synthetic gene encoding human GDH will enable us to generate a large number of site-directed mutations at several positions in the coding region. The high level of GDH expression as a soluble protein in E. coli will facilitate the purification of large quantities of mutant proteins for biochemical and structural studies. This combination of genetic and biochemical techniques could be used to address a broad range of questions relating to the structure and function of human GDH.
